TW202227143A - 放射性藥物及方法 - Google Patents

放射性藥物及方法 Download PDF

Info

Publication number
TW202227143A
TW202227143A TW110131903A TW110131903A TW202227143A TW 202227143 A TW202227143 A TW 202227143A TW 110131903 A TW110131903 A TW 110131903A TW 110131903 A TW110131903 A TW 110131903A TW 202227143 A TW202227143 A TW 202227143A
Authority
TW
Taiwan
Prior art keywords
acid
dotatate
amount
compounds
octreonic
Prior art date
Application number
TW110131903A
Other languages
English (en)
Chinese (zh)
Inventor
喬 麥肯
賈斯蒂娜 凱莉
保羅 比隆
Original Assignee
加拿大商探針開發暨商業化中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加拿大商探針開發暨商業化中心 filed Critical 加拿大商探針開發暨商業化中心
Publication of TW202227143A publication Critical patent/TW202227143A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110131903A 2020-08-27 2021-08-27 放射性藥物及方法 TW202227143A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063071138P 2020-08-27 2020-08-27
US63/071,138 2020-08-27

Publications (1)

Publication Number Publication Date
TW202227143A true TW202227143A (zh) 2022-07-16

Family

ID=80352743

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110131903A TW202227143A (zh) 2020-08-27 2021-08-27 放射性藥物及方法

Country Status (9)

Country Link
US (2) US11439714B2 (https=)
EP (1) EP4204011A4 (https=)
JP (1) JP2023540240A (https=)
KR (1) KR20240121161A (https=)
CN (1) CN116528904A (https=)
AU (1) AU2021330382A1 (https=)
CA (1) CA3190855A1 (https=)
TW (1) TW202227143A (https=)
WO (1) WO2022043754A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
EP4178628A4 (en) 2020-07-13 2025-04-02 Point Biopharma, Inc. RADIOPHARMACEUTICALS AND PROCEDURES
JP2025505307A (ja) * 2022-03-02 2025-02-21 ポイント・バイオファーマ・インコーポレイテッド 放射性医薬品及び方法
CN115015441B (zh) * 2022-07-14 2023-08-18 原子高科股份有限公司 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法
US12514939B2 (en) 2024-02-14 2026-01-06 Alpha-9 Oncology, Inc. Stable radiopharmaceutical compositions and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1096278A (en) 1913-08-25 1914-05-12 American Radiator Co Service-outlet fitting for pneumatic cleaning systems.
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6358245B1 (en) 1998-02-19 2002-03-19 Curon Medical, Inc. Graphical user interface for association with an electrode structure deployed in contact with a tissue region
US7297143B2 (en) 2003-02-05 2007-11-20 Arthrocare Corporation Temperature indicating electrosurgical apparatus and methods
JP5139678B2 (ja) 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
JP2018518526A (ja) * 2015-06-25 2018-07-12 アドバンスド アクセレレーター アプリケーションズ ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法
CA3035415A1 (en) 2016-05-23 2017-11-30 Imperial Innovations Limited Surgical instrument, robotic arm and control system for a robotic arm
US10537399B2 (en) 2016-08-16 2020-01-21 Ethicon Llc Surgical tool positioning based on sensed parameters
US10537394B2 (en) 2016-12-19 2020-01-21 Ethicon Llc Hot device indication of video display
US10596276B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596278B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
WO2020064693A1 (en) * 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
CA3159337A1 (en) * 2018-10-31 2020-05-07 Advanced Accelerator Applications (Italy) Srl Methods for synthesis of radionuclide complex

Also Published As

Publication number Publication date
JP2023540240A (ja) 2023-09-22
AU2021330382A1 (en) 2023-05-04
KR20240121161A (ko) 2024-08-08
US11439714B2 (en) 2022-09-13
US20220062447A1 (en) 2022-03-03
US20220387637A1 (en) 2022-12-08
CA3190855A1 (en) 2022-03-03
CN116528904A (zh) 2023-08-01
EP4204011A4 (en) 2025-06-18
WO2022043754A2 (en) 2022-03-03
WO2022043754A3 (en) 2022-04-07
EP4204011A2 (en) 2023-07-05
AU2021330382A9 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
TW202227143A (zh) 放射性藥物及方法
US12558440B2 (en) Radiopharmaceutical and methods
US11129912B1 (en) Radiopharmaceutical and methods
CN1033143C (zh) 放射性药物制剂的制备方法
JP7358451B2 (ja) 安定な濃厚放射性核種錯体溶液
TW202123976A (zh) 穩定濃縮之放射性醫藥組合物
JP2004517854A (ja) 安定化放射性医薬組成物
CN101257929B (zh) 包含龙胆酸的稳定的123-i放射性药物
CN116547007A (zh) 放射性药物和方法
JP2025505307A (ja) 放射性医薬品及び方法
CN118742332A (zh) 放射性药物和方法
HK40088578A (zh) 放射性药物和方法
CN114569545A (zh) 一种稳定的米托蒽醌制剂
RU2859685C2 (ru) Фармацевтическая композиция в форме раствора для внутривенного введения на основе металлокомплексов бета-эмиттеров: лютеций-177 или тербий-161 и агонистов соматостатиновых рецепторов: DOTA-TATE, DOTA-TOC, DOTA-NOC
CN114569544A (zh) 一种米托蒽醌注射剂的制备方法